Logo Immatics

Merger with Arya Sciences Acquisition Corp. and subsequent Nasdaq listing

USD 149 million (pipe USD 104 million)
Financial Adviser
;

Immatics

Financial adviser

Kempen & Co is pleased to announce that it acted as financial adviser in Immatics’ business combination with Arya Sciences Acquisition Corp., thereby becoming a Nasdaq listed company and securing USD 253 million

Transaction highlights

  • Immatics completed a business combination with Arya Sciences Acquisition Corp., a special purpose acquisition company (SPAC), resulting in the first Nasdaq listing via a SPAC of a European-based life sciences company
  • The Company will receive proceeds of approximately USD 253 million which includes USD 149 million from Arya’s trust account and USD 104 million is committed through a PIPE led by Perceptive Advisors, other top-tier US healthcare investors and existing Immatics investors, several of which are clients of Kempen & Co
  • Immatics will commence trading its shares on the Nasdaq Capital Market as of today
  • Kempen & Co was the sole European financial advisor in an otherwise US-led financial advisor syndicate
  • Building on our experience of the Q4 2019 Nasdaq IPO of Germany-based BioNTech, Kempen & Co advised on its second Germany-based company with its entry to Nasdaq

Company description

Immatics is a Germany-based clinical-stage biopharmaceutical company that combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for its pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as its partnerships with global leaders in the pharmaceutical industry. Immatics is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Background Kempen Life Sciences & Healthcare

Over the past year, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

  • Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
  • Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
  • Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
  • Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
  • Co-Manager in the USD 862 million Global Offering by argenx
  • Joint Bookrunner in the SEK 1,414 million Capital Increase by Oncopeptides
  • Co-Manager in the USD 154 million Global Offering of DBV Therapeutics
  • Joint Global Coordinator and Joint Bookrunner in the €19.0 million Capital Increase by Sequana Medical
  • Lead Manager in the USD 557 million Global Offering by argenx
  • Co-Manager in the USD 79.2 million US Public Offering by Merus
  • Co-Manager in the USD 57.5 million Capital Increase by ProQR
  • Co-Manager in the USD 150 million Nasdaq IPO of BioNTech
  • Sole Bookrunner in the €9.0 million Capital Increase by MDxHealth
  • Co-Manager in the USD 20.0 million Global Offering of Celyad
  • Co-Manager in the USD 582 million NASDAQ IPO of Genmab
  • Joint Bookrunner in the €116 million Secondary Sale of Fagron shares by Waterland and Baltisse
  • Joint Bookrunner in the €48.7 million Rights Issue by Transgene
  • Joint Bookrunner in the SEK 727 million Capital Increase by Oncopeptides

Contact

Jan De Kerpel
Nadine Maalouf
Kathrin Erfurth

Transactions